A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: inside (292)

Papers CoG 16.07.2025

Description
Date Time Location Chair Agenda Council of Governors 16/07/2025 14:00 - 15:30 Conference Room, Heartbeat/Microsoft Teams Jenni Doug
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Governors/Papers-CoG-16.07.2025.pdf

Papers CoG - 29.01.2025

Description
Date Time Location Chair Agenda Council of Governors 29/01/2025 14:00 - 15:30 Conference Room, Heartbeat/Microsoft Team
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Governors/Papers-CoG-29.01.2025.pdf

Papers CoG 23.10.2024

Description
Date Time Location Chair Agenda Council of Governors 23/10/2024 14:35 - 16:15 Conference Room, Heartbeat/Microsoft Teams Jenni
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Governors/Papers-CoG-23.10.2024.pdf

Atezolizumab SC-Carboplatin(AUC5)-Etoposide (IV/PO)

Description
Chemotherapy Protocol LUNG CANCER– SMALL CELL (SCLC) ATEZOLIZUMAB-SC-CARBOPLATIN (AUC5)-ETOPOSIDE(IV/PO) Regimen • L
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Atezolizumab-SC-CarboplatinAUC5-Etoposide-IVPO.pdf

EDI Champion role descriptor_final 180924

Description
Job Title: NIHR Southampton BRC Equity Champion Salary: Clinical Academic 2PAs / non-Clinical Academics 0.2 WTE Department: Trust HQ, NIHR Southa
Url
/Media/Southampton-Clinical-Research/Downloads/EDI-Champion-role-descriptor-final-180924.pdf

Atezolizumab-Bevacizumab-Carboplatin(AUC6)-Paclitaxel

Description
Chemotherapy Protocol LUNG CANCER ATEZOLIZUMAB-BEVACIZUMAB-CARBOPLATIN (AUC6)-PACLITAXEL Regimen  Lung
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Atezolizumab-Bevacizumab-CarboplatinAUC6-Paclitaxel.pdf

Papers Council of Governors 19 October 2022

Description
Agenda attachments 1 CoG Agenda - 19.10.2022.docx Date Time Location Chair Agenda Council of Governors 19/10/2022 14
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Council-of-Governors-19-October-2022.pdf

Durvalumab(28day-1500mg)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indicatio
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

Nivolumab 240mg (NSCLC)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Nivolumab (240mg-14 days) Regimen • NSCLC – Nivolumab (240mg-14days) Indicatio
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Nivolumab-240mg.pdf

Nivolumab 480mg (renal)

Description
Chemotherapy Protocol RENAL CELL CANCER Nivolumab (480mg-28 days) Regimen • Renal Cell – Nivolumab (480mg-28 days) Indication • Nivolumab is recommende
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Nivolumab-480mg.pdf
101 to 110 of 1000
Previous … 9 10 11 12 13 … Next